Cervarix

Cervarix Use In Pregnancy & Lactation

vaccine, human papillomavirus types 16 and 18 (recombinant)

Manufacturer:

GlaxoSmithKline Indonesia
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: The effect of Cervarix on embryo-foetal, peri-natal and post-natal survival and development has been assessed in rats. Such animal studies do not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryonal/foetal development, parturition or post-natal development.
Data in pregnant women collected as part of clinical trials, pregnancy registries, and epidemiological studies do not suggest that vaccination with Cervarix alters the risk of abnormal outcomes in neonates including birth defects. Data are insufficient to conclude whether or not vaccination with Cervarix affects the risk of spontaneous abortion.
Women who are pregnant or trying to become pregnant, are advised to postpone vaccination until completion of pregnancy.
Lactation: The effect on breast-fed infants of the administration of Cervarix to their mothers has not been evaluated in clinical studies.
Cervarix should only be used during breast-feeding when the possible advantages outweigh the possible risks.
Serological data suggest a transfer of antiHPV16 and antiHPV18 antibodies via the milk during the lactation period in rats. However, it is unknown whether vaccine-induced antibodies are excreted in human breast milk.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in